Although zoledronate inhibits prostate cancer proliferation through ERK/Akt inactivation and synergizes with panobinostat in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways, zoledronate inhibits the MAPK and induced apoptosis of hepatoma cells [11, 32, 33]. Here, AKT1 is linked to AL amyloidosis.